What does JP4653109 cover for obinutuzumab in Japan?
JP4653109 is a Japan patent publication that is commonly connected to obinutuzumab-related IP in Japan, and it appears in search results alongside “patent term extension” queries. Based on the information provided in the question alone, I can’t confirm exactly what claim set or drug product the document corresponds to, nor the exact reason for any extension (for example, whether it’s a patent term extension under Japan’s system for patents tied to regulatory approval delays).
To answer precisely (what the patent covers, what was extended, and for how long), I would need at least one of the following:
- a link to JP4653109, or
- the patent number with a title/assignee, or
- the official “patent term extension” (PTE) registration details tied to obinutuzumab in Japan.
How does Japan’s patent term extension work for medicines like obinutuzumab?
Japan can extend the term of certain patents to compensate for time spent during the regulatory approval process. For biologics and antibody drugs, the relevant “extension” depends on which patent is eligible and how it relates to obtaining marketing approval for the approved product.
Because the question is specifically about “obinutuzumab japan patent term extension jp4653109,” the key missing detail is whether JP4653109 is:
- the base patent being extended, and
- which specific approval/marketing authorization it is tied to.
Without the document or the PTE registration record, I can’t reliably state the mechanism, eligibility basis, or the resulting extended expiration date.
When would the extended patent expire in Japan (and how is the date calculated)?
The extended expiration date depends on:
- the filing/grant timeline of the underlying patent,
- the marketing authorization date used for the extension calculation, and
- any limits on extension length under Japan’s rules.
Your question asks about a specific identifier (JP4653109), but the extension end date requires the PTE registration details (or at least the underlying patent term and approval date link). Those aren’t included in the prompt.
Is JP4653109 the base patent or the PTE registration?
A common source of confusion in Japan is mixing:
- the publication/patent document number (e.g., JP4653109), with
- the separate patent term extension record/registration.
If you paste the text from the “patent term extension” section (or share a link to the Japan Patent Office record), I can tell you which is which and what the extension is actually doing for obinutuzumab.
What should you check next to verify freedom-to-operate timing in Japan?
For obinutuzumab, timing questions usually turn on verifying the right IP objects and their status. If you want, share the JP4653109 record link and I’ll map out:
- the patent family members,
- the legal status (in force/expired),
- whether a patent term extension exists,
- and the extended expiration date that matters for generic/biosimilar entry.
---
What I need from you to answer this accurately
Please provide one of the following:
1) a link to JP4653109 (Japan Patent Office / J-PlatPat page), or
2) the patent title and assignee from the JP4653109 record, plus any PTE registration number/date shown there, or
3) a screenshot/text of the “patent term extension” section from the record.
Once you share that, I can give the exact answer on what was extended and the resulting expiration date for obinutuzumab in Japan tied to JP4653109.